Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Curis (CRIS) Stock Price

Media coverage about Curis (NASDAQ:CRIS) has trended somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Curis earned a daily sentiment score of 0.11 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 46.2680092258257 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

These are some of the news headlines that may have effected Accern’s scoring:

A number of equities research analysts have recently issued reports on the company. Guggenheim assumed coverage on Curis in a research note on Monday, October 23rd. They issued a “buy” rating and a $7.00 target price for the company. Zacks Investment Research lowered Curis from a “hold” rating to a “sell” rating in a research note on Friday, November 10th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $6.50.

Curis (NASDAQ CRIS) traded down $0.01 during mid-day trading on Friday, hitting $0.55. The stock had a trading volume of 908,240 shares, compared to its average volume of 1,550,000. The company has a current ratio of 5.15, a quick ratio of 5.15 and a debt-to-equity ratio of 1.24. Curis has a fifty-two week low of $0.48 and a fifty-two week high of $3.22. The firm has a market capitalization of $88.31, a price-to-earnings ratio of -1.40 and a beta of 1.56.

ILLEGAL ACTIVITY WARNING: This news story was originally published by Community Financial News and is owned by of Community Financial News. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at

Curis Company Profile

Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.

Insider Buying and Selling by Quarter for Curis (NASDAQ:CRIS)

Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit